Resonant Medical Appoints New Vice President of Global Sales

    MONTREAL, Sept. 10 /CNW Telbec/ - Resonant Medical, the world leader in
3D ultrasound image-guided adaptive radiotherapy products, announced today
that Mr. Joe Redfearn has joined the Company as Vice President Global Sales.
This is a new position for Resonant Medical, and in this role, Mr. Redfearn
will be responsible for the Company's global sales and customer support
activities. He will also contribute to the expansion of the international
distribution network.
    "Mr. Redfearn brings to Resonant a track record of successful capital
equipment sales and support management," said Steve Arless, Resonant's
president & CEO. "His experience in the US and international marketplaces will
help us achieve our bold goals for the coming years.
    Mr. Redfearn joins the Company from Stereotaxis, where he was
Vice-President of Capital Sales. He is a seasoned executive that has grown in
the medical device industry for over 25 years, where he has worked for
CryoCath Technologies, ThermoCardio Systems and CR Bard. "I'm excited to join
the Resonant Medical Team and look forward to leading Resonant's efforts
toward profitable revenue growth" commented Redfearn. "With new top management
and proven product performance, Resonant is well-positioned for significant
sales growth."

    About Resonant Medical and Restitu(TM)

    Resonant Medical Inc. is the world leader in 3D ultrasound image-guided
radiotherapy products designed to improve treatment planning, verification and
delivery. Recently, the company secured significant financing in order to
develop and market Restitu(TM) add-on modules that will improve the quality of
radiotherapy treatment for patients with breast, head & neck, cervix, bladder,
and other soft tissue malignancies. These modules will compliment the
previously released prostate module and Restitu(TM) platform, which are
already in use in dozens of cancer clinics and university hospitals in North
    The Restitu(TM) Platform accurately visualizes and corrects daily changes
in tumor position, shape and size, thus ushering in a new era of 3D ultrasound
(U/S) multimodality radiotherapy treatment planning and image guidance.
Installed in CT-Sim rooms, Restitu U/S-Sim(TM) allows for better definition of
planning tumor volumes with its patented IMPLICIT REGISTRATION(TM) technology
that automatically fuses 3D U/S to CT data. With U/S-Sim, multimodality
treatment planning has now been made possible and affordable for all clinics,
with or without PET or MRI. Installed in treatment rooms, Restitu
U/S-Guide(TM) allows for highly accurate patient position verification and
alignment, with its proprietary MUTUAL REFERENCING(TM) technology that uses
assisted segmentation for efficient and robust intramodality 3D U/S

For further information:

For further information: Michèle Jémus, Chief Financial Officer,
Resonant Medical, (514) 985-2442 x 270, F.: (514) 985-9662,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890